thesi updat way sugar coat isnt
realli silver line either unfortun challeng cordi
disappoint tax rate somewhat confound
also headwind impact loss pmc continu
hsd deflat custom repric lead modest growth despit
like tax tailwind magnitud matter updat forecast core
profit declin pharma medic show modest expans due
synergi captur inventori cordi relief aggress
think realist rang like hope rest
sell side heed manag caution modest growth mean
mind lower all-in given question
challeng dont see share go much higher anytim soon
reason price-to-earnings rang base growth expect view
stock lower half rang given
reiter rate lower pt
main question becom make
given updat tend think pharma great
stabl result repres also acknowledg lot long
term question exist around distribut complex broadli thu
reaction total surpris us conclus recent ralli
distributor nice didnt last long expect skeptic remain
view point think multipl continu stuck
ldd time unfortun
continu see strong demand execut navihealth
medic servic busi
compani renew optum contract quarter
contract extend end
oper cost inventori reserv continu challeng
cordi came higher expect quarter expect
cordi path profit growth end
compani expect gener deflat wors year
mid-hsd vs prior msd
continu next page
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect object
report investor consid report singl factor make invest decis
chang
 lower updat view cordi worsen tax rate
 optum repres half custom plan initi
 anticip oper challeng cordi continu
 challeng previous expect
 custom repric larg share repric
 re-price custom year
 normal cours busi
 loss pharmerica
 see modest ep growth
 provid specif guidanc august
 cordi path profit growth end
higher expect tax rate result neg impact ep
 relat current forecast result cordi
receiv mm net proce feb divestur china distribut busi
 segment profit less anticip
 strong perform red oak enough off-set gener deflat
 strong flu season contribut off-set
 extend expand relationship
 contract extend
util dedic custom initi
 vast major spent year piec custom initi
 saw spend opioid initi expect rest spent
moder last year sequenti last quarter
wouldnt character aggress price market moder much origin anticip
brand inflat unchang
segment high teen excl patient recoveri vs prior flat
 driven primarili cordi
 also lesser extent brand product includ exam glove continu challeng
achiev margin rate primarili due cordi
patient recoveri busi continu track make good progress integr
 tsa exit begin summer
 lot work done meet expect
 see progress intent market
 china sale dd
 oper cost inventori reserv continu challeng
 came higher expect quarter
 compani abil understand demand signal turn manufactur plan
visibl consign inventori well compani particularli outsid us much
difficult origin expect
 recent launch new global suppli chain platform better inventori visibl
 work underway follow focus
 implement new process tech improv better management cordi consign inventori
 refocus product portfolio enhanc effici profit
 cordi path profit growth end
continu hit mileston
brought expert pharma side join team medic
us much smaller volum outsid us vs cordi
consign inventori differ type visibl vs cordi
 inventori standpoint littl concern
 downturn cordi perform creat loss certain jurisdict cant take benefit oper
loss tax perspect
overal tax reform benefit expect see declin tax rate go forward
 net posit
jon giacomin ceo medic
 tremend track record lot knowledg medic busi
chang leader cordi busi who current run asia pac busi within cordi
cardin health stat million except per share data fy end june organ gp growth revenu margin growth revenu ep share net incom price-to-earnings premium/discount isi healthcar technolog distribut may
valuat methodolog base mix discount cash flow analysi rel valuat multipl
risk valuat includ regulatori risk overal market risk well unforeseen event relat individu cover
compani broader sector includ new competit product technolog
laboratori corp america hold
articl articl
time dissemin may et
analyst ross muken elizabeth anderson suzi yoon primarili respons prepar research report attest
follow view opinion render research report reflect person view subject compani issuer
part research analyst compens directli relat specif recommend view
